SPY001 vs Zotemtegrast

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Ulcerative Colitis

Shared mechanism: α4β7 integrin · full Ulcerative Colitis pipeline

SPY001

Developed by Spyre Therapeutics

Phase 2 in Ulcerative Colitismonoclonal antibody (long-acting anti-α4β7)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: June 2027 · NCT07012395 (registry estimate)

No aligned efficacy figure on record for this race.

Zotemtegrast

Developed by Eli Lilly

Phase 2 in Ulcerative ColitisSmall molecule (oral α4β7 integrin inhibitor)
Weak signal

NCT05291689 · Phase 2 · completed

This was a single-group, open-label study with 39 participants overall and no placebo or active comparator. The primary clinical/histopathology endpoint was reported as a mean change, but without a comparator there was no formal between-group comparison to establish efficacy.

Next expected readout: May 2027 · NCT07186101 (registry estimate)

Reported efficacy

Percentage of Participants in Clinical Remission as Determined Using the Modified Mayo Clinic Score (mMCS) (Week 12): Percentage of Participants in Clinical Remission as Determined Using the Modified Mayo Clinic Score (mMCS) (Week 12): MORF-057 200 mg BID 31.9% | MORF-057 100 mg BID 23.9% | MORF-057 100 mg QD-M 17.1% vs Placebo 24.3% (missed)

Result source: NCT05611671

Results for Ulcerative Colitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointSPY001Zotemtegrast
Clinical remission (induction)—Not reported31.9% vs 24.3%+7.6 vs placebo200 mg BID · wk 12 · n 69NCT05611671
2 other results
  • 23.9% vs 24.3% 100 mg BID · wk 12 · n 71 · Phase 2 · primary NCT05611671
  • 17.1% vs 24.3% 100 mg QD-M · wk 12 · n 70 · Phase 2 · primary NCT05611671
Clinical remission (maintenance)—Not reported—Not reported
Clinical response (induction)—Not reported62.3% vs 54.3%+8 vs placebo200 mg BID · wk 12 · n 69NCT05611671
2 other results
  • 53.5% vs 54.3% 100 mg BID · wk 12 · n 71 · Phase 2 · secondary NCT05611671
  • 57.1% vs 54.3% 100 mg QD-M · wk 12 · n 70 · Phase 2 · secondary NCT05611671
Endoscopic improvement (induction)—Not reported—Not reported
Corticosteroid-free remission (maintenance)—Not reported—Not reported

Clinical remission (induction)

SPY001
—Not reported
Zotemtegrast
31.9% vs 24.3%+7.6 vs placebo200 mg BID · wk 12 · n 69NCT05611671
2 other results
  • 23.9% vs 24.3% 100 mg BID · wk 12 · n 71 · Phase 2 · primary NCT05611671
  • 17.1% vs 24.3% 100 mg QD-M · wk 12 · n 70 · Phase 2 · primary NCT05611671

Clinical remission (maintenance)

SPY001
—Not reported
Zotemtegrast
—Not reported

Clinical response (induction)

SPY001
—Not reported
Zotemtegrast
62.3% vs 54.3%+8 vs placebo200 mg BID · wk 12 · n 69NCT05611671
2 other results
  • 53.5% vs 54.3% 100 mg BID · wk 12 · n 71 · Phase 2 · secondary NCT05611671
  • 57.1% vs 54.3% 100 mg QD-M · wk 12 · n 70 · Phase 2 · secondary NCT05611671

Endoscopic improvement (induction)

SPY001
—Not reported
Zotemtegrast
—Not reported

Corticosteroid-free remission (maintenance)

SPY001
—Not reported
Zotemtegrast
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

SPY001: no structured comparison results are available for Ulcerative Colitis.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. SPY001: 0 of 4 rows · Zotemtegrast: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricZotemtegrast
Dropout rate
75%MORF-057 (Exploratory Cohort)
NCT05291689 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
show 4 more results
51.4%MORF-057 (Main Cohort)
NCT05291689 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
5.8%200 mg BID
NCT05611671 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
4.2%100 mg BID
NCT05611671 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
4.3%100 mg QD-M
NCT05611671 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
Discontinued due to AEs
75%MORF-057 (Exploratory Cohort)
NCT05291689 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
show 4 more results
8.6%MORF-057 (Main Cohort)
NCT05291689 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
1.4%200 mg BID
NCT05611671 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
1.4%100 mg BID
NCT05611671 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
0%100 mg QD-M
NCT05611671 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
Serious AEs
0%MORF-057 (Exploratory Cohort)
NCT05291689 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
show 4 more results
0%MORF-057 (Main Cohort)
NCT05291689 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
1.4%200 mg BID
NCT05611671 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
4.2%100 mg BID
NCT05611671 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
0%100 mg QD-M
NCT05611671 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
Most frequent reported AEs
colitis ulcerative 100%
anaemia 25%
erythema 25%
NCT05291689 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
show 4 more results
colitis ulcerative 20%
anaemia 8.6%
acne 5.7%
NCT05291689 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
200 mg BID
headache 7.1% (placebo 2.9%)
nasopharyngitis 4.3% (placebo 5.8%)
anaemia 2.9% (placebo 5.8%)
NCT05611671 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
100 mg BID
headache 5.6% (placebo 2.9%)
nasopharyngitis 4.2% (placebo 5.8%)
anaemia 2.8% (placebo 5.8%)
NCT05611671 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
100 mg QD-M
anaemia 4.3% (placebo 5.8%)
headache 2.9% (placebo 2.9%)
nasopharyngitis 0% (placebo 5.8%)
NCT05611671 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Zotemtegrast

RHI -6.4 score @ 12wk
absolute change · score
No placebo or comparator arm
NCT05291689 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
Mayo Clinic -2.3 score @ 12wk
absolute change · score
No placebo or comparator arm
NCT05291689 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
Clinical Remission 31.9% (n=69) vs 24.3% (n=70) placebo @ 12wk200 mg BID
responder rate · % of participants
NCT05611671 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
show 2 more results
23.9% (n=71) vs 24.3% (n=70) placebo @ 12wk100 mg BID
NCT05611671 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
17.1% (n=70) vs 24.3% (n=70) placebo @ 12wk100 mg QD-M
NCT05611671 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
Clinical Response 62.3% (n=69) vs 54.3% (n=70) placebo @ 12wk200 mg BID
responder rate · % of participants
NCT05611671 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
show 2 more results
53.5% (n=71) vs 54.3% (n=70) placebo @ 12wk100 mg BID
NCT05611671 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
57.1% (n=70) vs 54.3% (n=70) placebo @ 12wk100 mg QD-M
NCT05611671 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: SPY001's landscape · Zotemtegrast's landscape